<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453529</url>
  </required_header>
  <id_info>
    <org_study_id>W-4873-101</org_study_id>
    <nct_id>NCT02453529</nct_id>
  </id_info>
  <brief_title>Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects</brief_title>
  <official_title>A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, multiple dose, open-label pharmacokinetic study conducted in healthy adult&#xD;
      male and female subjects.&#xD;
&#xD;
      Subjects will receive 3 oral doses of WCK 4873 administered once-daily starting on Day 1.&#xD;
      Blood collection for determining plasma WCK 4873 concentrations will be conducted within 15&#xD;
      minutes prior to and at 1, 2, 3, 4, 6, 9, 12, and 24 hours after the first dose of WCK 4873.&#xD;
      The 24 hours post-dose sample after the first dose will be collected prior to Day 2 dosing.&#xD;
      Blood samples for determining plasma WCK 4873 concentrations will also be collected within 15&#xD;
      minutes prior to and at 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours after the third dose. Each&#xD;
      subject will undergo one standardized bronchoscopy with bronchoalveolar lavage (BAL) in the&#xD;
      outpatient bronchoscopy suite at 3, 6, 9, 12, 24 or 48 hours after the third oral dose of WCK&#xD;
      4873. Subjects scheduled for bronchoscopy at 48 hours will also have blood sample drawn for&#xD;
      determining plasma WCK 4873 concentrations at 48 hours after the third dose.&#xD;
&#xD;
      Safety will be assessed throughout the study by adverse event monitoring, clinical laboratory&#xD;
      tests (including liver function tests), ECG, physical examination and vital sign monitoring.&#xD;
      Subjects will discontinue study drug administration in the event of AST/ALT elevation of&#xD;
      greater than 3 times the upper limit of normal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Epithelial lining fluid (ELF) and alveolar macrophage (AM) will be used to assess the concentrations of oral WCK 4873 in healthy adult subjects</measure>
    <time_frame>48 hrs per dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Safety and tolerability of oral WCK 4873 in healthy adult subjects as measure by safety lab assesments, ECGs, physical examinations and AEs captured.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Pharmacokinetic (PK) profile of multiple doses (800 mg) of WCK 4873 in healthy adult subjects</measure>
    <time_frame>48 hrs last dose</time_frame>
    <description>Plasma concentrations of WCK 4873; plasma PK parameters (Cmax, tmax, kel, t½, AUC0-t, AUC0-24, Vd, CL); ELF concentrations of WCK 4873; concentration of WCK 4873 in alveolar macrophages</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>WCK 4873</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WCK 4873</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>WCK 4873</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) 18.5 and 30 (kg/m2) and weight between 55.0 and 100.0 kg (both&#xD;
             inclusive).&#xD;
&#xD;
          -  Medical history without any major pathology as judged by the Principal Investigator.&#xD;
&#xD;
          -  Resting supine blood pressure 100-139 (systolic) or 60-89 (diastolic) mm Hg, a resting&#xD;
             pulse rate of 40 beats per minute or higher, and showing no clinically relevant&#xD;
             deviations as judged by the Principal Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant oncologic, cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease.&#xD;
&#xD;
          -  Positive alcohol breath test or urine drug screen test at screening or confinement.&#xD;
&#xD;
          -  Positive testing for HIV, Hepatitis B or Hepatitis C.&#xD;
&#xD;
          -  Clinically significant pulmonary or any other disease that prevents a subject from&#xD;
             undergoing bronchoscopy with pulmonary lavage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Associates, 1112 E. McDowell Rd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plasma concentration</keyword>
  <keyword>pulmonary concentration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

